Anton Burkhard-Meier

TIM-3 Qualifies as a Potential Immunotherapeutic Target in Specific Subsets of Patients with High-Risk Soft Tissue Sarcomas (HR-STS)

F. Klauschen, L. Lindner, A. Altendorf-Hofmann, 2023, Cancers.

Implementing precision oncology for sarcoma patients: the CCCLMUmolecular tumor board experience

F. Klauschen, P. Greif, V. Heinemann, 2023, Journal of Cancer Research and Clinical Oncology.

Treatment of metastatic alveolar soft part sarcoma with axitinib and pembrolizumab in an 80-year-old patient with a history of autoimmune disorders.

J. Holch, L. Lindner, T. Knösel, 2022, Anti-Cancer Drugs.